scholarly journals Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)—PathIES

2019 ◽  
Vol 175 (1) ◽  
pp. 149-163 ◽  
Author(s):  
Zsolt Szijgyarto ◽  
Koen D. Flach ◽  
Mark Opdam ◽  
Carlo Palmieri ◽  
Sabine C. Linn ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Treatment Response ◽  
Predictive Value ◽  
Primary Breast Cancer ◽  
Receptor Phosphorylation

Development of an Evidence-Based Approach to External Quality Assurance for Breast Cancer Hormone Receptor Immunohistochemistry: Comparison of Reference Values

2011 ◽  
Vol 135 (7) ◽  
pp. 874-881
Author(s):  
Nikita Makretsov ◽  
C. Blake Gilks ◽  
Reza Alaghehbandan ◽  
John Garratt ◽  
Louise Quenneville ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Quality Assurance ◽  
Progesterone Receptor ◽  
Reference Values ◽  
Predictive Value ◽  
External Quality Assurance ◽  
Evidence Based ◽  
External Quality ◽  
Test Sensitivity

Abstract Context.—External quality assurance and proficiency testing programs for breast cancer predictive biomarkers are based largely on traditional ad hoc design; at present there is no universal consensus on definition of a standard reference value for samples used in external quality assurance programs. Objective.—To explore reference values for estrogen receptor and progesterone receptor immunohistochemistry in order to develop an evidence-based analytic platform for external quality assurance. Design.—There were 31 participating laboratories, 4 of which were previously designated as “expert” laboratories. Each participant tested a tissue microarray slide with 44 breast carcinomas for estrogen receptor and progesterone receptor and submitted it to the Canadian Immunohistochemistry Quality Control Program for analysis. Nuclear staining in 1% or more of the tumor cells was a positive score. Five methods for determining reference values were compared. Results.—All reference values showed 100% agreement for estrogen receptor and progesterone receptor scores, when indeterminate results were excluded. Individual laboratory performance (agreement rates, test sensitivity, test specificity, positive predictive value, negative predictive value, and κ value) was very similar for all reference values. Identification of suboptimal performance by all methods was identical for 30 of 31 laboratories. Estrogen receptor assessment of 1 laboratory was discordant: agreement was less than 90% for 3 of 5 reference values and greater than 90% with the use of 2 other reference values. Conclusions.—Various reference values provide equivalent laboratory rating. In addition to descriptive feedback, our approach allows calculation of technical test sensitivity and specificity, positive and negative predictive values, agreement rates, and κ values to guide corrective actions.

scholarly journals Neoadjuvant endocrine therapy for estrogen receptor-positive primary breast cancer

2020 ◽  
Vol 9 (3) ◽  
pp. 30-30
Author(s):  
Yutaka Yamamoto ◽  
Lisa Goto-Yamaguchi ◽  
Masako Takeno ◽  
Mutsuko Yamamoto-Ibusuki
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Endocrine Therapy ◽  
Primary Breast Cancer ◽  
Neoadjuvant Endocrine Therapy ◽  
Estrogen Receptor Positive

scholarly journals Sequential estrogen receptor determinations from primary breast cancer and at relapse: Prognostic and therapeutic relevance

1992 ◽  
Vol 3 (9) ◽  
pp. 733-740 ◽  
Author(s):  
V. Spataro ◽  
K. Price ◽  
A. Goldhirsch ◽  
F. Cavalli ◽  
E. Simoncini ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Primary Breast Cancer ◽  
Therapeutic Relevance

Phosphorylation of Estrogen Receptor β at Serine 105 in Primary Breast Cancer.

2009 ◽  
Author(s):  
W. Hamilton-Burke ◽  
A. Shaaban ◽  
M. Cummings ◽  
D. Holliday ◽  
S. Pollock ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Primary Breast Cancer ◽  
Estrogen Receptor Β

Microsomal Epoxide Hydrolase Expression as a Predictor of Tamoxifen Response in Primary Breast Cancer: A Retrospective Exploratory Study With Long-Term Follow-Up

2001 ◽  
Vol 19 (1) ◽  
pp. 3-9 ◽  
Author(s):  
Peter Fritz ◽  
Thomas E. Mürdter ◽  
Michel Eichelbaum ◽  
Isabel Siegle ◽  
Matthias Weissert ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Prognostic Factor ◽  
Exploratory Study ◽  
Primary Breast Cancer ◽  
Epoxide Hydrolase ◽  
Disease Outcome ◽  
Tamoxifen Treatment ◽  
Microsomal Epoxide Hydrolase

PURPOSE: It has been suggested that estrogen receptor–independent high-affinity binding sites for antiestrogens could limit their local bioavailability and response. Microsomal epoxide hydrolase (mEH) was recently shown to be a component of the antiestrogen binding site complex. We investigated whether mEH expression in primary breast tumors is related to disease outcome and to the efficacy of tamoxifen treatment. PATIENTS AND METHODS: Expression of mEH was semiquantitatively assessed by immunohistochemistry in sections prepared from archival paraffin blocks of primary breast cancers from 179 patients with a mean follow-up time of 81 months. RESULTS: Expression of mEH was correlated with poor disease outcome in all patients (P < .01; n = 179) and in patients receiving tamoxifen (P < .01; n = 78), but not in patients not treated with tamoxifen. Moreover, mEH was an independent prognostic factor by Cox regression analysis. CONCLUSION: The results of this first exploratory study suggest that mEH expression in primary breast cancer could be of predictive value for response to tamoxifen treatment and/or may be a novel independent prognostic factor for survival. The results are in agreement with the model that mEH participates in an estrogen receptor–independent tamoxifen- binding complex.

Muss der ER-Grenzwert neu definiert werden?

2018 ◽  
Vol 50 (02) ◽  
pp. 82-84
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Clinical Oncology ◽  
Primary Breast Cancer ◽  
Estrogen Receptor Positivity ◽  
American Society ◽  
Definition Of ◽  
Er Expression

Fujii T, Kogawa T, Dong W et al. Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer. Ann Oncol 2017; 28: 2420–2428 Gemäß den Empfehlungen der „American Society of Clinical Oncology“ sowie der Fachgesellschaft der US-Pathologen werden Mammakarzinome mit einer ER-Expression < 1% als rezeptornegativ bewertet. Wissenschaftliche Untersuchungen deuten jedoch darauf hin, dass diese Tumoren in molekulargenetischer und prognostischer Hinsicht Karzinomen mit einer ER-Expression zwischen 1 und 9% ähneln. Sollte der Grenzwert angehoben werden?

Real-time ultrasound elastography for monitoring tumor response to neoadjuvant chemotherapy in primary breast cancer

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 14023-14023 ◽  
Author(s):  
H. Bando ◽  
M. Ishii ◽  
E. Tohno ◽  
E. Ueno
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Real Time ◽  
Predictive Value ◽  
Primary Breast Cancer ◽  
Tumor Response ◽  
Residual Tumor ◽  
Term Survival ◽  
Pathological Cr ◽  
Response To Neoadjuvant Chemotherapy

14023 Background: Response to neoadjuvant treatment is vital to predict a patient’s long-term survival. Precise detection of residual tumor cells after neoadjuvant chemotherapy would allow a better cosmetic results avoiding over surgery and reduce second operation due to positive margin status. Moreover, accurate prediction of pathological CR will yield no surgical intervention in certain population. Recently, a new generation of ultrasound platforms with real-time freehand elastography that enables the imaging of elasticity of the lesion by using the extended combined autocorrelation method (CAM) has become available. We are currently applying this technology to our patients with primary breast cancer in an attempt to assess response to neoadjuvant chemotherapy in comparison with MRI, conventional ultrasound and pathological findings. Methods: A total of 38 patients with primary breast cancer who underwent neoadjuvant chemotherapy and following surgical resection From May 2005 to Dec 2006 were included in this study. Board certified radiologists assessed the tumor response by MRI, US and US Elastography prior to surgery. Positive predictive value (PPV), and negative predictive value (NPV) for pathological CR (pCR) was assessed. Tsukuba Elastography score was applied for the assessment of Elastography. Results: 11/38 patients (28.9%) achieved a pCR in breast to neoadjuvant chemotherapy while no patients demonstrated progressive disease. The PPV for pCR of MRI and US was 54.5% and 36.3% respectively. The NPV of MRI and US was both 90.9%. None of the residual tumor mass with score 4 or 5 cases diagnosed by Elastography achieved pCR. When residual tumor image was detected by US, pCR was present in all 4 cases with score 1 or 2 Elatography. If the cut-off line is determined between score 3 and 4, the PPV and NPV for pCR by Elastography was 100% and 66.6% respectively. Conclusions: Elastography is easy to perform and it can provide an inexpensive, non-invasive, real-time tool for assessment of response to neoadjuvant chemotherapy among patients with primary breast cancer. In particular, Elastography might more effectively diagnose pathological CR. More patients are needed to evaluate the sensitivity and specificity of this new technology. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document